BioSpectator Inc Highlights Optioned EGFR Degrader and Expanding Oncology Pipeline in Weekly Roundup

BioSpectator Inc this week highlighted several oncology developments across its portfolio companies and covered partners, underscoring momentum in targeted therapies and immuno-oncology. A key focus was AstraZeneca’s decision to exercise its option on Pinetree Therapeutics’ EGFR bispecific antibody degrader PTX-299, securing global rights.

The PTX-299 deal, executed in under two years, includes more than $500 million in potential milestones plus royalties, reflecting strong big-pharma interest in pan-EGFR degradation strategies. BioSpectator’s coverage notes that PTX-299’s lysosomal degradation approach could complement or challenge existing EGFR TKIs if future data are supportive.

BioSpectator also reported extensively on Compass Therapeutics’ Phase 2/3 COMPANION-002 trial of DLL4xVEGF bispecific antibody tovecimig in second-line biliary tract cancer. The data showed a 56% reduction in risk of progression or death with the tovecimig plus paclitaxel regimen, establishing a clear progression-free survival benefit.

However, overall survival results appeared numerically worse in the tovecimig arm, with the company attributing this to a 54% crossover rate from control to active therapy. Subgroup analyses suggested longer survival for crossover patients, but the mixed OS picture introduces regulatory uncertainty as Compass prepares for a pre-BLA meeting with the U.S. FDA.

In the targeted protein degradation space, BioSpectator detailed Hanmi Pharmaceutical’s oral EP300 degrader program for solid tumors, which remains in lead optimization. Early in vivo signals and the absence of observed thrombocytopenia differentiate it from EP300/CBP dual inhibitors, while oral bioavailability is positioned as a competitive strength.

BioSpectator noted that Hanmi is using machine learning to refine indication selection, highlighting a data-driven approach at an early stage of development. Although still preclinical, the program underscores growing competition and innovation around EP300 as a solid-tumor target within the TPD field.

The company further spotlighted ReCerise Therapeutics’ first-in-class TM4SF5 antibody RCT1213, which could enter clinical trials as early as next year. TM4SF5 is highly expressed in several gastrointestinal cancers, and RCT1213 aims to remodel the tumor microenvironment from immune-resistant to immune-permissive.

ReCerise’s oral presentation at AACR 2026 was cited as a marker of scientific interest that may support future partnering or financing. While still preclinical, the program could position ReCerise and BioSpectator for value inflection if human data validate TM4SF5 as a druggable target in hard-to-treat GI cancers.

BioSpectator’s broader weekly recap also emphasized Korean immuno-oncology and ADC innovation, including Y-Biologics’ trispecific IL-2 antibody strategy and ABL Bio’s B7-H3xROR1 and EGFRxMUC1 ADCs. Multiple assets are approaching IND or early clinical milestones, pointing to a steadily maturing regional oncology ecosystem.

Taken together, the week’s updates portray BioSpectator-linked companies advancing a diversified set of novel modalities, from antibody-based degraders and bispecifics to TPD and TME-targeting antibodies. These developments collectively enhance the long-term optionality of the broader portfolio while maintaining typical early-stage biotech risk profiles.